1992
DOI: 10.1111/j.1365-2044.1992.tb01999.x
|View full text |Cite
|
Sign up to set email alerts
|

Editorial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1995
1995
2011
2011

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 21 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…5 The enantiomers of local anesthetics may differ in terms of pharmacokinetic and pharmacodynamic properties, with resultant differences in clinical local anesthetic action and toxicity. 12 As the cardiotoxicity of d-bupivacaine is higher than that of the l-enantiomer, 13 the antibacterial properties of the enantiomers may also differ. This would warrant further study.…”
Section: Discussionmentioning
confidence: 99%
“…5 The enantiomers of local anesthetics may differ in terms of pharmacokinetic and pharmacodynamic properties, with resultant differences in clinical local anesthetic action and toxicity. 12 As the cardiotoxicity of d-bupivacaine is higher than that of the l-enantiomer, 13 the antibacterial properties of the enantiomers may also differ. This would warrant further study.…”
Section: Discussionmentioning
confidence: 99%
“…The other enantiomer can have undesirable properties, have different therapeutic activities or be pharmacologically inert. [57] It is thus a logical and safer approach to avoid the presence of the therapeutically useless but potentially harmful isomer (‘isomeric ballast’) in drug formulations. [8]…”
Section: Basic Conceptsmentioning
confidence: 99%